Eda Elverici

Eda Elverici

Auto-generated profile, based on publicly available information

Eda Elverici

Ankara Bilkent City Hospital

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2016 in Journal of the Belgian Society of Radiology
Verified
Journal Article
Open access
PDF file
MÇMehtap Çavuşoğlu
Mehtap Çavuşoğlu
DCDeniz Sözmen Ciliz
Deniz Sözmen Ciliz
AOArzu Ozsoy
Arzu Ozsoy
SDSemra Duran
Semra Duran
EEEda Elverici
Eda Elverici
BSBulent Sakman
Bulent Sakman
To investigate the feasibility of diffusion-weighted magnetic resonance imaging (DWI) with apparent diffusion coefficient (ADC) values in differentiating endometrial cancer from benign endometrial lesions in postmenopausal patients with vaginal bleeding and endometrial thickening and to predict the depth of myometrial invasion in endometrial cancer. Postmenopausal patients with vaginal bleeding and endometrial thickening were enrolled in this prospective study. T2-weighted, pre- and postcontrast T1-weighted and diffusion-weighted images were obtained. The ADC values of all the patients with endometrial pathologies were recorded. The staging accuracies of DWI and postcontrast T1-weighted images in the assessment of myometrial invasion were evaluated in histopathologically proven endometrial cancer patients. Fifty-two patients (mean age: 57 ± 10, range: 41-79) were enrolled in the study. Thirty-eight of the lesions were benign (27 as hyperplasia and endometritis; 11 as polyps). Fourteen of the 52 endometrial lesions were pathologically proven as cancers and underwent hysterectomy, and all the specimens were reported as endometrioid adenocarcinomas. The mean ADC value (10-3 mm2/second) of cancer (0.88 ± 0.10) was significantly lower than that of benign lesions (1.78 ± 0.27, p = 0,001). There was no significant difference between ADC values of endometrial tissue in patients with FIGO stage 1A (0.87 ± 0.11, n = 9) and FIGO stage 1B (0.91 ± 0.07, n = 5). The staging accuracy was 92.9 per cent (13/14) for DWI and 85.7 per cent (12/14) for postcontrast T1-weighted images. ADC values allow benign endometrial lesions to be differentiated from endometrial cancer in postmenopausal patients but do not correlate with the depth of myometrial invasion and histological tumor grading.

1 February 2015 in Journal of the Belgian Society of Radiology
Verified
Journal Article
Open access
PDF file
SDS. Duran
S. Duran
MCM. Cavusoglu
M. Cavusoglu
EEE. Elverici
E. Elverici
TUT. D. Unal
T. D. Unal
Sciatic hernia is a rare condition and its clinical diagnosis is uneasy. Herniation of pelvic organs as well as of retroperitoneal neoplasm has been reported in the literature. Sciatica occurs as a result of compression of the sciatic nerve by the herniated sac. We present a case of retroperitoneal lipoma in a patient who had lower leg complaint and describe the imaging findings.

1 July 2023 in Diagnostic and Interventional Radiology
Verified
Journal Article
Open access
AOAyşenur Oktay
Ayşenur Oktay
ÖAÖzge Aslan
Özge Aslan
FTFüsun Taşkın
Füsun Taşkın
NTNermin Tuncbilek
Nermin Tuncbilek
GIGul ESEN ICTEN
Gul ESEN ICTEN
NÖNecmettin Özdemir
Necmettin Özdemir
The clinical management of high-risk lesions using image-guided biopsy is challenging. This study aimed to evaluate the rates at which such lesions were upgraded to malignancy and identify possible predictive factors for upgrading high-risk lesions. This retrospective multicenter analysis included 1.343 patients diagnosed with high-risk lesions using an image-guided core needle or vacuum-assisted biopsy (VAB). Only patients managed using an excisional biopsy or with at least one year of documented radiological follow-up were included. For each, the Breast Imaging Reporting and Data System (BI-RADS) category, number of samples, needle thickness, and lesion size were correlated with malignancy upgrade rates in different histologic subtypes. Pearson's chi-squared test, the Fisher-Freeman-Halton test, and Fisher's exact test were used for the statistical analyses. The overall upgrade rate was 20.6%, with the highest rates in the subtypes of intraductal papilloma (IP) with atypia (44.7%; 55/123), followed by atypical ductal hyperplasia (ADH) (38.4%; 144/375), lobular neoplasia (LN) (12.7%; 7/55), papilloma without atypia (9.4%; 58/611), flat epithelial atypia (FEA) (8.7%; 10/114), and radial scars (RSs) (4.6%; 3/65). There was a significant relationship between the upgrade rate and BI-RADS category, number of samples, and lesion size Lesion size was the most predictive factor for an upgrade in all subtypes. ADH and atypical IP showed considerable upgrade rates to malignancy, requiring surgical excision. The LN, IP without atypia, pure FEA, and RS subtypes showed lower malignancy rates when the BI-RADS category was lower and in smaller lesions that had been adequately sampled using VAB. After being discussed in a multidisciplinary meeting, these cases could be managed with follow-up instead of excision.

24 January 2023 in Balkan Medical Journal
Verified
Journal Article
Open access
EEEda Elverici
Eda Elverici
AÖArzu Özsoy
Arzu Özsoy
BSBige Sayın
Bige Sayın
MGMuhammet Batuhan Gökhan
Muhammet Batuhan Gökhan
EOERDEM OZKAN
ERDEM OZKAN
Currently, unilateral clinical and subclinical axillary adenopathy cases associated with the Pfizer-BioNTech and Moderna vaccines are increasingly reported. However, only one study on axillary adenopathy due to the CoronaVac vaccine is published. To present the incidence, severity, and ultrasonographic findings of axillary adenopathy that developed in healthcare professionals in Turkey after they were vaccinated with CoronaVac against coronavirus disease-19. A prospective study. In Turkey, the first dose of the CoronaVac vaccine for coronavirus disease-19 was administered to healthcare professionals on January 14, 2021, and the second dose on February 11, 2021. This study covered the period from January 21, 2021 (1 week after the first dose), and April 15, 2021 (9 weeks after the second dose). Individuals who had a history of COVID-19 more than 3 weeks after vaccine doses, systemic disease, and diagnosis and treatment history of breast cancer were excluded. The axillary lymph nodes of the vaccinated and contralateral arms were evaluated in 101 volunteer healthcare professionals using axillary ultrasonography. A significant difference was found in the cortical thicknesses of the lymph nodes between the vaccinated and contralateral axilla after both the first (*p < 0.01) and second (*p < 0.01) doses. Accordingly, the rates of subclinical lymphatic hyperplasia on the vaccinated side were 25.7% (n = 26/101) after the first and 31.1% (n = 28/90) after the second dose. Lymph nodes with pathological appearance based on a reduced echogenic hilum with marked cortical thickening were found only in 2.2%. Among the 39 cases in which antibodies (immunoglobulin G and immunoglobulin M) were measured, the antibody level was classified as <10 and ≥10. No statistically significant difference was found in the cortical thickness of the axillary lymph nodes between patients with high antibody levels (≥10) and those with low antibody levels (<10) (p > 0.05). In this study, clinical signs of axillary lymph node hyperplasia were not detected after vaccination with CoronaVac. Mild and diffuse thickening of the CoronaVac vaccine-induced lymph nodes was more common than pathological and palpable lymph nodes.

6 October 2025 in Acta Radiologica
Verified
Journal Article
Closed access
EEEda Elverici
Eda Elverici
SGSeçil Gündoğdu
Seçil Gündoğdu
LKLeman Gunbey Karabekmez
Leman Gunbey Karabekmez
SKSerra Kayaçetin
Serra Kayaçetin
BÖBuket Altun Özdemir
Buket Altun Özdemir
AÖArzu Özsoy
Arzu Özsoy
Background: Contrast-enhancing magnetic resonance imaging is an expensive examination compared to contrast-enhanced spectral mammography (CESM) and cannot show microcalcifications. Purpose: To investigate the diagnostic performance of CESM for malignancy with microcalcifications alone and the relationship between tumor immunohistochemistry findings and tumor grade. Material and Methods: A total of 117 patients with suspected microcalcification at CESM were applied to our hospital between January 2022 and May 2024. Patients with accompanying mass and architectural distortion (n = 9) and the ones lacking pathology results (n = 11) were excluded. Patients with CESM and histopathological diagnosis (n = 97) were evaluated retrospectively. Mammography images were analyzed according to the American College of Radiology Breast Imaging-Reporting and Data System lexicon. Results: In our study, the diagnostic value of the presence of contrast enhancement in CESM was high in the evaluation of suspicious breast microcalcifications. Malignant pathology was detected in all of the microcalcifications with high-risk morphology. In addition, all of the microcalcifications that enhanced in solid and ground-glass form were invasive ductal carcinoma. However, no significant relationship was found between immunohistochemical parameters (ER, PR, CerB2, Ki-67 and grade) and enhancement in CESM. The highest enhancement rate among malignant subtypes was detected in the luminal B group. Conclusion: CESM is useful to reduce the number of unnecessary benign biopsies with suspicious microcalcifications in the breast, and provides an important contribution to the radiologist's biopsy decision by simultaneously showing the morphological features of the microcalcification and the contrast enhancement information.

12 August 2026 in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
SGSeçil Gündoğdu
Seçil Gündoğdu
EEEda Elverici
Eda Elverici
LKLeman Günbey Karabekmez
Leman Günbey Karabekmez
PSPelin Zeynep Bekin Sarıkaya
Pelin Zeynep Bekin Sarıkaya
Objective: To assess the contribution of magnetic resonance imaging to Breast Imaging Reporting and Data System (BI-RADS) reclassification and biopsy decision making in patients with non-mass breast lesions identified on ultrasound.Material and Methods: This retrospective study included 392 patients who underwent breast magnetic resonance imaging following the identification of non-mass breast lesions on ultrasound; 135 had histopathologic verification and were analyzed. BI-RADS categories on ultrasound and magnetic resonance imaging were compared, and reclassification patterns were defined as upgrade (ultrasound